Evofem Biosciences, Inc. announced that the United States Patent and Trademark Office (USPTO) issued to the Company a Notice of Allowance for patent application 16/738,868 entitled, "Compositions and Methods for Enhancing the Efficacy of Contraceptive Microbicides" which covers the composition of matter of Phexxi® (lactic acid, citric acid, potassium bitartrate) and is expected to provide protection into at least 2033. With the issuance of this patent, in the United States, Evofem will solely have the right to make, have made, market, and sell for any commercial purpose the composition of matter that comprises Phexxi.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0136 USD | -14.47% | +13.33% | -78.75% |
1st Jan change | Capi. | |
---|---|---|
-78.75% | 830K | |
+30.38% | 684B | |
+26.51% | 568B | |
-4.36% | 361B | |
+19.30% | 329B | |
+3.73% | 284B | |
+16.70% | 240B | |
+8.78% | 208B | |
-7.93% | 200B | |
+7.68% | 166B |
- Stock Market
- Equities
- EVFM Stock
- News Evofem Biosciences, Inc.
- Evofem Strengthens Phexxi® Intellectual Property with New Composition of Matter Patent from United States Patent and Trademark Office